Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.

被引：2
|
作者：
Pivot, Xavier
Bondarenko, Igor
Nowecki, Zbigniew
Dvorkin, Mikhail
Trishkina, Ekaterina
Sarosiek, Tomasz
Wojtukiewicz, Marek
Shparyk, Yaroslav V.
Moiseyenko, Vladimir
Kim, Younsoo
Lim, Jae Yun
机构：
[1] Adm Inst Reg Canc, Strasbourg, France
[2] Dnipropetrovsk Med Acad, Dnepropetrovsk, Ukraine
[3] Ctr Onkol Inst M Sklodowskiej Curie, Warsaw, Poland
[4] Omsk Reg Clin Ctr Oncol, Omsk, Russia
[5] SBHI Leningrad Reg Oncol Dispensary, St Petersburg, Russia
[6] Magodent Sp Zoo, Warsaw, Poland
[7] Med Univ, Ctr Comprehens Canc, Bialystok, Poland
[8] Lviv State Oncol Reg Med & Diagnost Ctr, Lvov, Ukraine
[9] Clin & Res Ctr Specialized Types Med Care Oncol, St Petersburg, Russia
[10] Samsung Bioepis Co Ltd, Suwon, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e12631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12631
引用
收藏
页数：2
相关论文
共 50 条
  • [1] One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment
    Pivot, X.
    Bondarenko, I. M.
    Nowecki, Z.
    Dvorkin, M.
    Trishkina, E.
    Ahn, J. H.
    Vinnyk, Y.
    Im, S-A.
    Sarosiek, T.
    Chatterjee, S.
    Wojtukiewicz, M.
    Moiseyenko, V.
    Shparyk, Y.
    Bello, M., III
    Semiglazov, V.
    Younju, L.
    Lim, J.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [2] Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.
    Pivot, Xavier
    Pegram, Mark D.
    Cortes, Javier
    Luftner, Diana
    Rugo, Hope S.
    Lyman, Gary H.
    Curigliano, Giuseppe
    Bondarenko, Igor
    Dvorkin, Mikhail
    Yoon, Ye Chan
    Kim, Younsoo
    Kim, Chul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
    Pivot, X.
    Bondarenko, I.
    Nowecki, Z.
    Dvorkin, M.
    Trishkina, E.
    Ahn, J. -H.
    Im, S. -A.
    Sarosiek, T.
    Chatterjee, S.
    Wojtukiewicz, M. Z.
    Shparyk, Y.
    Moiseyenko, V.
    Bello, M., III
    Semiglazov, V.
    Lee, Y.
    Lim, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 93 : 19 - 27
  • [4] 3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting
    Pivot, X.
    Bondarenko, I.
    Dvorkin, M.
    Sarosiek, T.
    Wojtukiewicz, M.
    Shparyk, Y.
    Kim, Y.
    Lim, J.
    [J]. BREAST, 2019, 44 : S68 - S68
  • [5] Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer
    Pivot, Xavier
    Pegram, Mark D.
    Cortes, Javier
    Luftner, Diana
    Lyman, Gary H.
    Curigliano, Giuseppe
    Bondarenko, Igor M.
    Dvorkin, Mikhail
    Ahn, Jin Hee
    Im, Seock-Ah
    Litwiniuk, Maria
    Shparyk, Yaroslav V.
    Ho, Gwo Fuang
    Kislov, Nikolay V.
    Wojtukiewicz, Marek
    Sarosiek, Tomasz
    Chae, Yee Soo
    Ahn, Jin Seok
    Jang, Hyerin
    Kim, Sujung
    Lee, Jiwon
    Lee, Soo Young
    Yoon, Ye Chan
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [6] Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer
    Pivot, X.
    Burian, O.
    Bazan, F.
    Wojtukiewicz, M.
    Jang, H.
    Kim, S.
    Lee, J.
    Yoon, Y. C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S428 - S428
  • [7] Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.
    Pivot, Xavier
    Pegram, Mark D.
    Cortes, Javier
    Luftner, Diana
    Lyman, Gary H.
    Curigliano, Giuseppe
    Bondarenko, Igor
    Yoon, Ye Chan
    Kim, Younsoo
    Lim, Jae Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Event-free survival by ADCC status from a follow-up study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab for HER2 positive breast cancer in neoadjuvant setting
    Pegram, M. D.
    Pivot, X.
    Cortes, J.
    Curigliano, G.
    Yoon, Y.
    Lim, J.
    Song, S.
    Hong, E.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [9] Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
    Suppan, Christoph
    Steiner, Daniel
    Klocker, Eva Valentina
    Posch, Florian
    Henzinger, Elisabeth
    Mueller, Hannah Deborah
    Stoeger, Herbert
    Dandachi, Nadia
    Balic, Marija
    [J]. BREAST CARE, 2021, 16 (06) : 607 - 613
  • [10] A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer
    Pivot, Xavier B.
    Bondarenko, Igor
    Dvorkin, Mikhail
    Trishkina, Ekaterina
    Ahn, Jin-Hee
    Im, Seock-Ah
    Sarosiek, Tomasz
    Chattopadhyay, Sanjay
    Wojtukiewicz, Marek
    Moiseyenko, Vladimir
    Shparyk, Yaroslav V.
    Bello, Maximino De Guzman
    Semiglazov, Vladimir
    Song, Sujeong
    Lim, Jae Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345